title: [Genetic and phenotypic analysis of heterogeneous population of a cold-adapted donor of the A/Leningrad/134/17/57 (H2N2) attenuation and of the donor-based reassortant influenza vaccine strains].
abstract: Cold-adapted (CA) temperature sensitive and attenuated virus A/Leningrad/134/17/57 (H2N2) (Len/17) has been recently used in Russia as a donor of internal genes in the preparation of reassortant vaccine strains of CA live influenza vaccine (LIV) for all age groups. The Len/17 population was found to be heterogeneous and to be made up of clones, which differ by combinations of mutations in internal genes. Around 50% of the Len/17 population had clones with all 8 coding mutations in internal genes. The others were made up of clones with mutation combinations, which were different from the original Len/17. The PCR restriction method was used to analyze 5 clones of Len/17 and 8 LIV vaccine strains. There were no Ala-86-Thr mutation in the M2 protein in 4 clones and 3 vaccine strains. The PB-1 gene of 4 clones and 3 vaccine strains had a mutation encoding Met-317-IIe more typical of a more attenuated virus A/Leningrad/134/47/57 (H2N2) (Len/47). The NP protein of a clone had a mutation Leu-341-IIe also typical of Len/47. However, neither the absence of mutation in the M2 gene nor an extra mutation in the PB1 gene affected the attenuation extent of reassortant CALIV.
authors.forename: I V
authors.initials: IV
authors.lastname: Kiseleva
authors.forename: A I
authors.initials: AI
authors.lastname: Klimov
authors.forename: E P
authors.initials: EP
authors.lastname: Grigor'eva
authors.forename: N V
authors.initials: NV
authors.lastname: Larionova
authors.forename: G I
authors.initials: GI
authors.lastname: Aleksandrova
authors.forename: L G
authors.initials: LG
authors.lastname: Rudenko
mesh_terms: D000293:Adolescent; D000328:Adult; D003080:Cold Temperature; D005334:Fever / Q000209:etiology; D005838:Genotype; D006801:Humans; D053121:Influenza A Virus, H2N2 Subtype; D009980:Influenza A virus / Q000235:genetics* / Q000254:growth & development; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics*; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology; D009154:Mutation; D009698:Nucleoproteins / Q000235:genetics; D010641:Phenotype; D016865:Reassortant Viruses / Q000235:genetics* / Q000254:growth & development; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics; D014763:Viral Matrix Proteins / Q000235:genetics; D014764:Viral Proteins / Q000235:genetics; D000086082:Viroporin Proteins
chemical_list: D007252:Influenza Vaccines; D009698:Nucleoproteins; D014613:Vaccines, Attenuated; D014763:Viral Matrix Proteins; D014764:Viral Proteins; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins; C077346:influenza virus polymerase basic protein 1